Suppression of STAT3 by chemically modified siRNAs increases the chemotherapeutic sensitivity of parental and cisplatin-resistant non-small cell lung cancer cells

Journal of B.U.ON.

Volumn 19, Issue 1, 2014, Pages 145-152

  Kaymaz, Burcin Tezcanli ^a   Cetintas, Vildan Bozok ^a   Eroglu, Zuhal ^a   Kosova, Buket ^a  

^a EGE UNIVERSITY   (Turkey)

Author keywords

Calul; Chemically modified siRNA; Cisplatin resistance; Non small cell lung cancer; STAT3

Indexed keywords

CASPASE 3; CISPLATIN; GLUCOSE 6 PHOSPHATE DEHYDROGENASE; MESSENGER RNA; SMALL INTERFERING RNA; STAT3 PROTEIN; STAT5A PROTEIN; STAT5B PROTEIN;

APOPTOSIS; ARTICLE; CANCER CELL; CANCER RESISTANCE; CELL PROLIFERATION; CELL VIABILITY; CONTROLLED STUDY; CYTOTOXICITY; ENZYME ACTIVATION; ENZYME ACTIVITY; GENE SILENCING; HUMAN; HUMAN CELL; LUNG NON SMALL CELL CANCER; NUCLEOSOME; NUCLEOTIDE SEQUENCE; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; UPREGULATION; WESTERN BLOTTING;

APOPTOSIS; CARCINOMA, NON-SMALL-CELL LUNG; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; CISPLATIN; DRUG RESISTANCE, NEOPLASM; HUMANS; RNA, SMALL INTERFERING; STAT3 TRANSCRIPTION FACTOR;

EID: 84898885818     PISSN: 11070625     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (39)

1. Silvestri GA, Alberg AJ,Ravenel J. The changing epidemiology of lung cancer with a focus on screening. BMJ 2009;339:b3053.
2. Youlden DR, Cramb SM, Baade PD. The international epidemiology of lung cancer; geographical distribution and secular trends. J Thorac Oncol 2008;3:819831.
3. Chu G. Cellular responses to cisplatin. The roles of DNA-binding proteins and DNA repair. J Biol Chem 1994;269:787-790.
4. El-Sherif A, Luketich JD, Landreneau RJ, Fernando HC. New therapeutic approaches for early stage nonsmall cell lung cancer. Surg Oncol 2005;14:27-32. (Pubitemid 40380620)
5. Timmer-Bosscha H, Mulder NH,de Vries EG. Modulation of cis-diamminedichloroplatinum(II) resistance: a review. Br J Cancer 1992;66:227-238.
6. Zambie DB, Lippard SJ. Cisplatin and DNA repair in cancer chemotherapy. Trends Biochem Sci 1995;20:435-439.
7. Darnell JE Jr. STATs and gene regulation. Science 1997;277:1630-1635.
8. Yu H, Jove R. The STATs of cancer-new molecular targets come of age. Nat Rev Cancer 2004;4:97-105. (Pubitemid 38198738)
9. Bromberg JF, Wrzeszczynska MH, Devgan G et al. Stat3 as an oncogene. Cell 1999;98:295-303. (Pubitemid 29380565)
10. Grandis JR, Drenning SD, Zeng Q et al. Constitutive activation of Stat3 signaling abrogates apoptosis in squamous cell carcinogenesis in vivo. Proc Natl Acad Sci U S A 2000;97:4227-4232. (Pubitemid 30226115)
11. He Y, Zhou Z, Hofstetter WL et al. Aberrant expression of proteins involved in signal transduction and DNA repair pathways in lung cancer and their association with clinical parameters. PLoS One 2012;7:e31087.
12. Kato K, Nomoto M, Izumi H et al. Structure and functional analysis of the human STAT3 gene promoter: alteration of chromatin structure as a possible mechanism for the upregulation in cisplatin-resistant cells. Biochim Biophys Acta 2000;1493:91-100.
13. Ikuta K, Takemura K, Kihara M et al. Overexpression of constitutive signal transducer and activator of transcription 3 mRNA in cisplatin-resistant human nonsmall cell lung cancer cells. Oncol Rep 2005;13:217-222.
14. Sen GL, Blau HM. A brief history of RNAi: the silence of the genes. FASEB J 2006;20:1293-1299. (Pubitemid 44943837)
15. Whitehead KA, Langer R, Anderson DG. Knocking down barriers: advances in siRNA delivery. Nat Rev Drug Discov 2009;8:129-138.
16. Chiu YL, Rana TM. siRNA function in RNAi: a chemical modification analysis. RNA 2003;9:1034-1048. (Pubitemid 37093614)
17. Engels JW. Gene silencing by chemically modified siRNAs. N Biotechnol 2013;30:302-307.
18. Kaymaz BT, Selvi N, Gunduz C et al. Repression of STAT3, STAT5A, and STAT5B expressions in chronic myelogenous leukemia cell line K-562 with unmodifled or chemically modified siRNAs and induction of apoptosis. Ann Hematol 2012;92:151-162.
19. Cetintas VB, Kucukaslan AS, Kosova B et al. Cispla- tin resistance induced by decreased apoptotic activity in non-small-cell lung cancer cell lines. Cell Biol Int 2012;36:261-265.
20. Kosova B, Tezcanli B, Ekiz HA et al. Suppression of STAT5A increases chemotherapeutic sensitivity in imatinib-resistant and imatinib-sensitive K562 cells. Leuk Lymphoma 2010;51:1895-1901.
21. Primiano T, Baig M, Maliyekkel A et al. Identification of potential anticancer drug targets through the selection of growth-inhibitory genetic suppressor elements. Cancer Cell 2003;4:41-53. (Pubitemid 36904160)
22. Rosen DG, Mercado-Uribe I, Yang G et al. The role of constitutively active signal transducer and activator of transcription 3 in ovarian tumorigenesis and prognosis. Cancer 2006;107:2730-2740. (Pubitemid 44845630)
23. Yin Z, Zhang Y, Li Y et al. Prognostic significance of STAT3 expression and its correlation with chemoresistance of non-small cell lung cancer cells. Acta Histochem 2012;114:151-158.
24. Su WP, Cheng FY, Shieh DB et al. PLGA nanoparticles codeliver paclitaxel and Stat3 siRNA to overcome cellular resistance in lung cancer cells. Int J Nanomedicine 2012;7:4269-4283.
25. Kulesza DW, Carre T, Chouaib S, Kaminska B. Silencing of the transcription factor STAT3 sensitizes lung cancer cells to DNA damaging drugs, but not to TNFalpha- and NK cytotoxicity. Exp Cell Res 2013;319:506-516.
26. Huang S, Chen M, Shen Y et al. Inhibition of activated Stat3 reverses drug resistance to chemotherapeutic agents in gastric cancer cells. Cancer Lett 2012;315:198-205.
27. Lee SO, Lou W, Qureshi KM et al. RNA interference targeting Stat3 inhibits growth and induces apoptosis of human prostate cancer cells. Prostate 2004;60:303309.
28. Pancotti F, Roncuzzi L, Maggiolini M, Gasperi-Campani A. Caveolin-1 silencing arrests the proliferation of metastatic lung cancer cells through the inhibition of STAT3 signaling. Cell Signal 2012;24:1390-1397.
29. Liu T, Peng H, Zhang M et al. Cucurbitacin B, a small molecule inhibitor of the Stat3 signaling pathway, enhances the chemosensitivity of laryngeal squamous cell carcinoma cells to cisplatin. Eur J Pharmacol 2010;641:15-22.
30. Yin ZJ, Jin FG, Liu TG et al. Overexpression of STAT3 potentiates growth, survival, and radioresistance of non-small-cell lung cancer (NSCLC) cells. J Surg Res 2011;171:675-683.
31. Zhu BR, Cai JM, Tang GS et al. Effects of STAT3 antisense oligonucleotide on proliferation and apoptosis of non-small cell lung cancer cell line A549. Ai Zheng 2007;26:820-827.
32. Zhang X, Zhang J, Wang L et al. Therapeutic effects of STAT3 decoy oligodeoxynucleotide on human lung cancer in xenograft mice. BMC Cancer 2007;149:1-11.
33. Barre B, Vigneron A, Perkins N et al. The STAT3 oncogene as a predictive marker of drug resistance. Trends Mol Med 2007;13:4-11.
34. O'Connor DS, Grossman D, Plescia J et al. Regulation of apoptosis at cell division by p34cdc2 phosphorylation of survivin. Proc Natl Acad Sci U S A 2000;97:13103-13107.
35. Lin L, Deangelis S, Foust E et al. A novel small molecule inhibits STAT3 phosphorylation and DNA binding activity and exhibits potent growth suppressive activity in human cancer cells. Mol Cancer 2010 Aug 16;9:217.
36. Ma J, Wang S, Zhao M et al. Therapeutic potential of cladribine in combination with STAT3 inhibitor against multiple myeloma. BMC Cancer 2011;255:111.
37. Yue P, Zhang X, Paladino D et al. Hyperactive EGF receptor, Jaks and Stat3 signaling promote enhanced colony-forming ability, motility and migration of cisplatin-resistant ovarian cancer cells. Oncogene 2012;31:2309-2322.
38. Alvarez JV, Greulich H, Sellers WR et al. Signal transducer and activator of transcription 3 is required for the oncogenic effects of non-small-cell lung cancer-associated mutations of the epidermal growth factor receptor. Cancer Res 2006;66:3162-3168.
39. Jemal A, Bray F, Center MM et al. Global cancer statistics. CA Cancer J Clin 2011;61:69-90.